1. Home
  2. BCSF vs ABUS Comparison

BCSF vs ABUS Comparison

Compare BCSF & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bain Capital Specialty Finance Inc.

BCSF

Bain Capital Specialty Finance Inc.

HOLD

Current Price

$12.20

Market Cap

838.7M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.48

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCSF
ABUS
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
838.7M
839.5M
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
BCSF
ABUS
Price
$12.20
$4.48
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$14.00
$5.00
AVG Volume (30 Days)
386.0K
1.9M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
14.61%
N/A
EPS Growth
N/A
55.26
EPS
0.05
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$239.71
P/E Ratio
$240.80
$5.07
Revenue Growth
N/A
128.21
52 Week Low
$11.82
$3.04
52 Week High
$15.84
$5.10

Technical Indicators

Market Signals
Indicator
BCSF
ABUS
Relative Strength Index (RSI) 37.21 54.41
Support Level $11.92 $4.15
Resistance Level $13.74 $4.60
Average True Range (ATR) 0.30 0.17
MACD -0.06 0.01
Stochastic Oscillator 27.79 56.25

Price Performance

Historical Comparison
BCSF
ABUS

About BCSF Bain Capital Specialty Finance Inc.

Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: